News | Clinical Trials | October 26, 2022

Partnership will enable 150+ sites in 22 states to accept patients for respiratory clinical trials involving precision imaging

Partnership will enable 150+ sites in 22 states to accept patients for respiratory clinical trials involving precision imaging

October 26, 2022 —  VIDA Diagnostics, Inc. (VIDA), the leader in imaging intelligence, has partnered with Wellspring Capital-backed RAYUS Radiology, a leading national provider of advanced diagnostic and interventional radiology, to onboard more than 150 locations as clinical trial imaging sites. Precision quantitative imaging is increasingly being leveraged by therapy developers in clinical trials; however, trial sites can be challenged by the demands of high-quality image acquisition and data management associated with trial imaging. VIDA and RAYUS are teaming up to address these challenges for imaging sites so they can participate in imaging-based clinical trials with greater ease.  

"To accelerate commercialization and improve patient access to clinical trials, pharmaceutical companies are increasingly relying on clinical trial decentralization, providing access for participants beyond major urban centers," said Amy Garrigues, Chief Strategy and Development Officer for RAYUS Radiology. "Thanks to our partnership with VIDA, we can provide an immediate boost to this effort across 22 states, bringing clinical trial level imaging together with disciplined data stewardship and operational oversight."

Each of RAYUS's 150+ locations will be able to connect to the VIDA Intelligence Portal, allowing for deeper data analysis, insights, and operational ease of imaging trials. Through VIDA's portal, hundreds of staff across these locations can be trained on and guided through protocols required for the data quality demands of imaging-based clinical trials. After certification, sites can engage with clinical trial sponsors and begin qualifying and onboarding trial participants. 

"This partnership is a win for all parties, enabling VIDA to expand our network of certified imaging sites for sponsors, providing RAYUS additional clinical trial opportunities, and giving patients greater accessibility to clinical trials," said Susan Wood, Ph.D., VIDA's president & CEO. "Most importantly, together we are addressing a major gap in the still too costly, inefficient and time-consuming drug development process – site location and convenience to patients, trial site capacity, consistency, and effectiveness. This partnership will help bridge the gap and accelerate new life enhancing therapies for patients." 

For more information: www.rayusradiology.com 


Related Content

News | Digital Pathology

June 15, 2026 — Leica Biosystems is expanding the availability of its Aperio GT Elite digital scanner into the EMEA ...

Time June 15, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

June 9, 2026 — An investigator at the Icahn School of Medicine at Mount Sinai has received international recognition for ...

Time June 15, 2026
arrow
News | Information Technology

June 9, 2026 — Mosaic Clinical Technologies, a wholly owned subsidiary of Radiology Partners, has launched Mosaic ...

Time June 15, 2026
arrow
News | Radiology Business

June 9, 2026 — Bayer has appointed Dr. Jost Reinhard president of the Radiology business within Bayer’s Pharmaceuticals ...

Time June 12, 2026
arrow
News | Imaging Software Development

June 10, 2026 — DeepHealth, Inc., a wholly owned subsidiary of RadNet, has launched Reporting Pro, an AI-powered ...

Time June 12, 2026
arrow
News | Enterprise Imaging

June 9, 2026 — GE HealthCare will showcase its latest enterprise imaging solutions at the Society for Imaging ...

Time June 09, 2026
arrow
News | Innovative Hospitals

May 27, 2026 — Nearly two years after announcing plans for a “real-world” academic-industrial collaboration, GE ...

Time June 03, 2026
arrow
News | Ultrasound Imaging

May 26, 2026 — A soft, wearable ultrasound patch that can continuously monitor a fetus for hours at a time — and it can ...

Time May 27, 2026
arrow
News | Radiopharmaceuticals and Tracers

May 27, 2026 — Subtle Medical has received FDA clearance for its SubtleHD (PET), the company's next-generation AI ...

Time May 27, 2026
arrow
News | FDA

May 19, 2026 — DeepHealth has received the CE Mark for the Brain Health and Brain Age solutions within its Neuro Suite ...

Time May 26, 2026
arrow
Subscribe Now